Antibody recognition of cancer-related gangliosides and their mimics investigated using in silico site mapping

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Agostino, Mark ^a   Yuriev, Elizabeth ^a   Ramsland, Paul A ^a,b,c  

^a MONASH UNIVERSITY   (Australia)

^b BURNET INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GANGLIOSIDE; GANGLIOSIDE ANTIBODY; PEPTIDE; CANCER ANTIBODY;

ANTIBODY DETECTION; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; GENE MAPPING; IMMUNE RESPONSE; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MIMICRY; MOLECULAR RECOGNITION; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN STRUCTURE; AMINO ACID SEQUENCE; ANTIBODY COMBINING SITE; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; EPITOPE MAPPING; HUMAN; HYDROGEN BOND; IMMUNOLOGY; MOLECULAR GENETICS; NEOPLASM; PROTEIN MOTIF; SURFACE PROPERTY;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANTIBODIES, NEOPLASM; BINDING SITES, ANTIBODY; COMPUTER SIMULATION; EPITOPE MAPPING; GANGLIOSIDES; HUMANS; HYDROGEN BONDING; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEOPLASMS; PEPTIDES; PROTEIN BINDING; SURFACE PROPERTIES;

EID: 84859941752     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035457     Document Type: Article

References (67)

1. Schnaar RL, (2010) Brain gangliosides in axon-myelin stability and axon regeneration. FEBS Letters 584: 1741-1747.
2. Posse de Chaves E, Sipione S, (2010) Sphingolipids and gangliosides of the nervous system in membrane function and dysfunction. FEBS Letters 584: 1748-1759.
3. Kusunoki S, Kaida K-i, (2011) Antibodies against ganglioside complexes in Guillain-Barre syndrome and related disorders. J Neurochem 116: 828-832.
4. Koga M, Yuki N, Hirata K, (1999) Subclass distribution and the secretory component of serum IgA anti-ganglioside antibodies in Guillain-Barre syndrome after Campylobacter jejuni enteritis. J Neuroimmunol 96: 245-250.
5. Neisser A, Schwerer B, Bernheimer H, Moran AP, (2000) Ganglioside-induced antiganglioside antibodies from a neuropathy patient cross-react with lipopolysaccharides of Campylobacter jejuni associated with Guillain-Barre syndrome. J Neuroimmunol 102: 85-88.
6. Hakomori S-I, (2001) Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol 491: 369-402.
7. Astronomo RD, Burton DR, (2010) Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov 9: 308-324.
8. Navid F, Santana VM, Barfield RC, (2010) Anti-GD2 antibody therapy for GD2-expressing tumors. Curr Cancer Drug Targets 10: 200-209.
9. Fernandez LE, Alonso DF, Gomez DE, Vazquez AM, (2003) Ganglioside-based vaccines and anti-idiotype antibodies for active immunotherapy against cancer. Exp Rev Vaccines 2: 817-823.
10. Fredman P, Hedberg K, Brezicka T, (2003) Gangliosides as therapeutic targets for cancer. Biodrugs 17: 155-167.
11. Diaz Y, Gonzalez A, Lopez A, Perez R, Vazquez AM, et al. (2009) Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma. Cancer Immunol Immunother 58: 1117-1128.
12. Cazet A, Julien S, Bobowski M, Burchell J, Delannoy P, (2010) Tumor-associated carbohydrate antigens in breast cancer. Breast Cancer Res 12: 204.
13. Wolchok JD, Livingston PO, (2001) Vaccines for melanoma: translating basic immunology into new therapies. Lancet Oncol 2: 205-211.
14. Inoue S, Sato C, Kitajima K, (2010) Extensive enrichment of N-glycolylneuraminic acid in extracellular sialoglycoproteins abundantly synthesized and secreted by human cancer cells. Glycobiology 20: 752-762.
15. Fernández LE, Gabri MR, Guthmann MD, Gomez RE, Gold S, et al. (2010) NGcGM3 ganglioside: a privileged target for cancer vaccines. Clin Dev Immunol 2010: 814397.
16. Chou HH, Takematsu H, Diaz S, Iber J, Nickerson E, et al. (1998) A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc Natl Acad Sci USA 95: 11751-11756.
17. Tangvoranuntakul P, Gagneux P, Diaz S, Bardor M, Varki N, et al. (2003) Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci USA 100: 12045-12050.
18. Mond JJ, Lees A, Snapper CM, (1995) T cell-independent antigens type 2. Annu Rev Immunol 13: 655-692.
19. Snapper CM, Mond JJ, (1996) A model for induction of T cell-independent humoral immunity in response to polysaccharide antigens. J Immunol 157: 2229-2233.
20. Agostino M, Sandrin MS, Thompson PE, Farrugia W, Ramsland PA, et al. (2011) Carbohydrate-mimetic peptides: structural aspects of mimicry and therapeutic implications. Expert Opin Biol Ther 11: 211-224.
21. Forster-Waldl E, Riemer AB, Dehof AK, Neumann D, Bramswig K, et al. (2005) Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen. Mol Immunol 42: 319-325.
22. Horwacik I, Czaplicki D, Talarek K, Kowalczyk A, Bolesta E, et al. (2007) Selection of novel peptide mimics of the GD2 ganglioside from a constrained phage-displayed peptide library. Int J Mol Med 19: 829-839.
23. Wondimu A, Zhang T, Kieber-Emmons T, Gimotty P, Sproesser K, et al. (2008) Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Cancer Immunol Immunother 57: 1079-1089.
24. Willers J, Lucchese A, Kanduc D, Ferrone S, (1999) Molecular mimicry of phage displayed peptides mimicking GD3 ganglioside. Peptides 20: 1021-1026.
25. Popa I, Ishikawa D, Tanaka M, Ogino K, Portoukalian J, et al. (2006) GD3-replica peptides selected from a phage peptide library induce a GD3 ganglioside antibody response. FEBS Letters 580: 1398-1404.
26. Horwacik I, Kurcinski M, Bzowska M, Kowalczyk AK, Czaplicki D, et al. (2011) Analysis and optimization of interactions between peptides mimicking the GD2 ganglioside and the monoclonal antibody 14G2a. Int J Mol Med 28: 47-57.
27. Vázquez AM, Pérez A, Hernández AM, Macías A, Alfonso M, et al. (1998) Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody. Hybridoma 17: 527-534.
28. Rodriguez M, Llanes L, Perez A, Perez R, Vazquez AM, (2003) Generation and characterization of an anti-idiotype monoclonal antibody related to GM3(NeuGc) ganglioside. Hybridoma Hybridomics 22: 307-314.
29. Krengel U, Olsson L-L, Talavera A, Rojas G, Mier E, et al. (2004) Structure and molecular interactions of a unique antitumor antibody specific for N-glycolyl GM3. J Biol Chem 279: 5597-5603.
30. Talavera A, Eriksson A, Okvist M, Lopez-Requena A, Fernandez-Marrero Y, et al. (2009) Crystal structure of an anti-ganglioside antibody, and modelling of the functional mimicry of its NeuGc-GM3 antigen by an anti-idiotypic antibody. Mol Immunol 46: 3466-3475.
31. Usuki S, Taguchi K, Gu Y-H, Thompson SA, Yu RK, (2010) Development of a novel therapy for Lipo-oligosaccharide-induced experimental neuritis: use of peptide glycomimics. J Neurochem 113: 351-362.
32. Agostino M, Sandrin MS, Thompson PE, Yuriev E, Ramsland PA, (2009) In silico analysis of antibody-carbohydrate interactions and its application to xenoreactive antibodies. Mol Immunol 47: 233-246.
33. Milland J, Yuriev E, Xing P.-X., McKenzie I.F.C., Ramsland PA, Sandrin MS, (2007) Carbohydrate residues downstream of the terminal Galα(1,3)Gal epitope modulate the specificity of xenoreactive antibodies. Immunol Cell Biol 85: 623-632.
34. Agostino M, Yuriev E, Ramsland PA, (2011) A computational approach for exploring carbohydrate recognition by lectins in innate immunity. Front Immunol 2: 23.
35. Yuriev E, Ramsland PA, Edmunson AB, (2001) Docking of combinatorial peptide libraries into a broadly cross-reactive human IgM. J Mol Recognit 14: 172-184.
36. Agostino M, Sandrin MS, Thompson PE, Ramsland PA, Yuriev E, (2011) Peptide inhibitors of xenoreactive antibodies mimic the interaction profile of the native carbohydrate antigens. Biopolymers 96: 193-206.
37. Yuriev E, Ramsland PA, Edmundson AB, (2002) Recognition of IgG-derived peptides by a human IgM with an unusual combining site. Scand J Immunol 55: 242-255.
38. Yuriev E, Sandrin MS, Ramsland PA, (2008) Antibody-ligand docking: insights into peptide-carbohydrate mimicry. Mol Simul 34: 461-468.
39. Lefranc M-P, Pommié C, Manuel R, Giudicelli V, Foulquier E, et al. (2003) IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev Comp Immunol 27: 55-77.
40. Schrödinger, LLC (2010) Glide, version 5.6. New York, NY.
41. Friesner RA, Banks JL, Murphy RB, Halgren TA, Kilcic JJ, et al. (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem2004: 1739-1749.
42. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD, (2003) Improved protein-ligand docking using GOLD. Proteins 52: 609-623.
43. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, et al. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19: 1639-1662.
44. Lang PT, Brozell SR, Mukherjee S, Pettersen EF, Meng EC, et al. (2009) DOCK 6: combining techniques to model RNA-small molecule complexes. RNA 15: 1219-1230.
45. Agostino M, Jene C, Boyle T, Ramsland PA, Yuriev E, (2009) Molecular docking of carbohydrate ligands to antibodies: structural validation against crystal structures. J Chem Inf Model 49: 2749-2760.
46. Schrödinger, LLC (2010) Maestro, version 9.2. New York, NY.
47. Schrödinger, LLC (2010) Prime, version 2.2. New York, NY.
48. Agostino M, Farrugia W, Sandrin MS, Scott AM, Yuriev E, et al. (2012) Structural glycobiology of antibody recognition in xenotransplantation and cancer immunotherapy. In: Kosma P, Müller-Loennies S, editors. Anticarbohydrate antibodies- from molecular basis to clinical application New York Springer pp. 203-228.
49. Yuriev E, Agostino M, Ramsland PA, (2011) Challenges and advances in computational docking: 2009 in review. J Mol Recognit 24: 149-164.
50. Nguyen HP, Seto NOL, MacKenzie CR, Brade L, Kosma P, et al. (2003) Germline antibody recognition of distinct carbohydrate epitopes. Nat Struct Biol 10: 1019-1025.
51. Brooks CL, Müller-Loennies S, Borisova SN, Brade L, Kosma P, et al. (2010) Antibodies raised against chlamydial lipopolysaccharide antigens reveal convergence in germline gene usage and differential epitope recognition. Biochemistry 49: 570-581.
52. Blackler RJ, Müller-Loennies S, Brooks CL, Evans DW, Brade L, et al. (2011) A common NH53K single point mutation in the combining site of antibodies raised against chlamydial LPS glycoconjugates significantly increases avidity. Biochemistry 50: 3357-3368.
53. Gorelik B, Goldblum A, (2008) High quality binding modes in docking ligands to proteins. Proteins 71: 1373-1386.
54. Al-Lazikani B, Lesk AM, Chothia C, (1997) Standard conformations for the canonical structures of immunoglobulins. J Mol Biol 273: 927-948.
55. Chothia C, Lesk AM, (1987) Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 196: 901-917.
56. James LC, Roversia P, Tawfik DS, (2003) Antibody multispecificity mediated by conformational diversity. Science 299: 1362-1367.
57. Herron JN, He XM, Ballard DW, Blier PR, Pace PE, et al. (1991) An autoantibody to single-stranded DNA: comparison of the three-dimensional structures of the unliganded Fab and a deoxynucleotide-Fab complex. Proteins 11: 159-175.
58. Krishnan L, Sahni G, Kaur KJ, Salunke DM, (2008) Role of antibody paratope conformational flexibility in the manifestation of molecular mimicry. Biophys J 94: 1367-1376.
59. Thielges MC, Zimmermann J, Yu W, Oda M, Romesberg FE, (2008) Exploring the energy landscape of antibody-antigen complexes: protein dynamics, flexibility, and molecular recognition. Biochemistry 47: 7237-7247.
60. Wilson IA, Stanfield RL, (1994) Antibody-antigen interactions: new structures and new conformational changes. Curr Opin Struct Biol 4: 857-867.
61. Ramsland PA, Farrugia W, Bradford TM, Hogarth PM, Scott AM, (2004) Structural convergence of antibody binding of carbohydrate determinants in Lewis Y tumor antigens. J Mol Biol 340: 809-818.
62. Agostino M, Sandrin MS, Thompson PE, Yuriev E, Ramsland PA, (2010) Identification of preferred carbohydrate binding modes in xenoreactive antibodies by combining conformational filters and binding site maps. Glycobiology 20: 724-735.
63. Nomenclature Committee, Consortium for Functional Glycomics. Symbol and text nomenclature for representation of glycan structure. Available from: http://glycomics.scripps.edu/CFGnomenclature.pdf. Accessed 2011 Dec 1.
64. Schrödinger, LLC (2010) The PyMOL Molecular Graphics System, Version 1.4.
65. Wallace AC, Laskowski RA, Thornton JM, (1995) LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions. Prot Eng 8: 127-134.
66. Kaminski MJ, MacKenzie CR, Mooibroek MJ, Dahms TE, Hirama T, et al. (1999) The role of homophilic binding in anti-tumor antibody R24 recognition of molecular surfaces. Demonstration of an intermolecular β-sheet between interaction between VH domains. J Biol Chem 274: 5597-5604.
67. Pichla SL, Murali R, Burnett RM, (1997) The crystal structure of a Fab fragment to the melanoma-associated GD2 ganglioside. J Struct Biol 119: 6-16.